Literature DB >> 17109653

Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats.

Dhvanit I Shah1, Manjeet Singh.   

Abstract

The study has been designed to investigate the effect of 8-Br-cAMP, an activator of protein kinase A, in hypertension-induced vascular endothelial dysfunction. Rats were uninephroctomized and desoxycortisone acetate (DOCA) (40 mg/kg, s.c.) was administered to rats to produce hypertension (mean arterial blood pressure > 140 mmHg). Vascular endothelial dysfunction was assessed using isolated aortic ring preparation, electron microscopy of thoracic aorta and serum concentration of nitrite/nitrate. The expression of mRNA for p22phox and eNOS was assessed by using reverse transcriptase-polymerase chain reaction. Serum thiobarbituric acid reactive substances concentration and aortic superoxide anion concentration were estimated to assess oxidative stress. 8-Br-cAMP (5 mg/kg, i.p.) or atorvastatin (30 mg/kg, p.o.) prevented hypertension-induced attenuation of acetylcholine-induced endothelium-dependent relaxation, impairment of vascular endothelial lining, decrease in expression of mRNA for endothelial nitric oxide synthase (eNOS), serum nitrite/nitrate concentration and increase in expression of mRNA for p22phox, superoxide anion and serum TBARS. The ameliorative effect of 8-Br-cAMP was prevented by N-nitro-L-arginine methyl ester (25 mg/kg, i.p.) and glibenclamide (30 mg/kg, i.p.). It may be concluded that 8-Br-cAMP may stimulate expression and activity of eNOS and suppress expression of p22phox subunit of NADPH oxidase to reduce oxidative stress and subsequently improve vascular endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109653     DOI: 10.1111/j.1472-8206.2006.00449.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  4 in total

1.  Oral Resolvin D1 attenuates early inflammation but not intimal hyperplasia in a rat carotid angioplasty model.

Authors:  Giorgio Mottola; Evan C Werlin; Bian Wu; Mian Chen; Anuran Chatterjee; Melinda S Schaller; Michael S Conte
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-12-10       Impact factor: 3.072

2.  Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes.

Authors:  A Riad; D Westermann; S Van Linthout; Z Mohr; S Uyulmaz; P M Becher; H Rütten; P Wohlfart; H Peters; H-P Schultheiss; C Tschöpe
Journal:  Diabetologia       Date:  2008-09-30       Impact factor: 10.122

3.  C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.

Authors:  Uma Singh; Sridevi Devaraj; Jeannette Vasquez-Vivar; Ishwarlal Jialal
Journal:  J Mol Cell Cardiol       Date:  2007-08-31       Impact factor: 5.000

Review 4.  Rodent animal models: from mild to advanced stages of diabetic nephropathy.

Authors:  Manpreet Kaur; Onkar Bedi; Shilpi Sachdeva; B V K Krishna Reddy; Puneet Kumar
Journal:  Inflammopharmacology       Date:  2014-08-23       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.